By Duke Medicine News and Communications
Durham, N.C. -- By imaging the beating hearts of mice using a
unique cardiac CT scanner developed by engineers at Duke
University Medical Center, the researchers believe they can
unlock many mysteries of heart disease.
To image the tiny mouse hearts -- about 3,000 times smaller
than a human heart -- the scanner achieves nearly 500 times the
resolution of clinically available CT scanners. What's more,
the mouse heart beats ten times faster, making the challenge of
capturing clear images of the pumping heart even more
difficult. Such problems led many radiologists to believe such
high-resolution images of living mouse hearts were technically
impossible.
"Transgenic manipulations in mice and rats are increasingly
used to study genetic and physiological aspects of human
cardiovascular disease—the leading cause of death in the United
States and major cause of death worldwide," said assistant
professor of radiology Cristian Badea, Ph.D., of the Duke
Center for In Vivo Microscopy. "However, cardiac studies in
small animals are not easy to do because of the animals' small
size and increased rate of biological functions."
The new scanner, however, will enable studies of the small
abnormalities in "transgenic" mice induced by mutating genes
involved in heart function, they said.
Despite their apparent differences, mice and humans share
many of the same genes. Therefore, mutant mice, or mouse
"models of disease," have become increasingly common to unravel
the underlying basis for diseases -- including cancer,
Parkinson's and heart disease -- and for advancing toward
possible new therapies.
Mouse models include "knockout" mice, which lack critical
genes, and those altered to overproduce proteins encoded by
particular disease-related genes. Such genetically-modified
animals typically display symptoms that mimic those observed in
patients affected with the disease.
However, characterizing those disease symptoms in mice
presents major challenges, Badea said. The high-resolution
images made possible by the newly developed micro-CT scanner
should help to overcome some of those hurdles, he said.
While clinical scanners rotate an X-ray tube and detector
around the patient, the newly developed system instead rotates
animals between a fixed tube and detector. The researchers also
place the mice on a mechanical ventilator, such that each
iteration of a scan can be synchronized with both the heart and
breathing motion, thereby reducing blurring of the image. The
researchers described the new system in the April-June 2005
Molecular Imaging.
"The cardiac CT images we are now getting are nearly 500
times higher resolution than the state-of-the-art in clinical
CT imaging," said G. Allan Johnson, director of the Duke
center. "The temporal resolution is also ten times greater than
that of the clinical arena."
The new scanner is the very first to take advantage of a new
class of molecular imaging agents designed to render blood
visible by X-ray scans, Johnson said. Unlike conventional
agents, which are rapidly cleared by the kidneys, the new
chemical, called Fenestra VC (Alerion Biomedical, San Diego,
CA) remains in the bloodstream for more than three hours.
The four-dimensional images produced by the micro-CT scanner
will not only allow researchers to capture "pretty images," but
also allow them to assess cardiac function in a manner
comparable to that used in clinical settings, Badea said. Using
computer software, developed by Pittsburgh Supercomputing
Center, for visualization and analysis, the researchers can
"slice" and analyze the images, he added.
"Recent reports have suggested that cardiac micro-CT in mice
would be impossible, even with state-of-the-art technology,"
Badea said. "With the development of our four-dimensional
scanner, we've proved this to be incorrect."
The Duke Center for In Vivo Microscopy provides imaging
resources to other Duke researchers, as well as researchers
nationally and internationally. The center is a National
Institutes of Health/National Center for Research Resources
National Resource. Additional support was provided by the
National Cancer Institute and the Department of Defense.